Multiple novel PDC agents are currently in clinical development, including TH1902 (targeting SORT1-positive advanced solid tumors, phase I trial), ANG1005 (for breast cancer brain metastases, phase II trial), and BT8009 (targeting nectin-4, phase I/II clinical trials) [26–28]. Here, PDC is linked to breast carcinoma.